3-ethoxy-1-ethyl-1H-pyrazol-4-amine | 1356543-57-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-ethoxy-1-ethyl-1H-pyrazol-4-amine
• 英文别名: 3-ethoxy-1-ethylpyrazol-4-amine
• CAS: 1356543-57-1
• 化学式: C₇H₁₃N₃O
• 分子量: 155.2
• InChiKey: JTKWRXVNTQNPOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  53.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] COMPOUNDS AND METHODS FOR INHIBITING JAK<br/>[FR] COMPOSÉS ET PROCÉDÉS D'INHIBITION DE JAK
  申请人：ASTRAZENECA AB

  公开号：WO2017050938A1

  公开（公告）日：2017-03-30

  Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: (I) wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and -CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, -(CH2)2OH and –(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.

  公开的是公式(I)的化合物，包括含有这些化合物的药物组合物以及使用这些化合物的方法/用途，例如用于治疗JAK相关疾病，如癌症、癌症恶病质或免疫紊乱：(I)其中R1是甲基或乙基；R2选择自甲基、乙基、甲氧基和乙氧基；R3选择自氢、氯、氟、溴和甲基；R4选择自甲基、乙基和- OCH3；R5和R6分别是甲基或氢；R7选择自甲基、乙基、-(CH2)2OH和-( )2OCH3，或其药用盐。
• Compounds and methods for inhibiting JAK
  申请人：Dizal (Jiangsu) Pharmaceutical Co., Ltd.

  公开号：US10167276B2

  公开（公告）日：2019-01-01

  Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.

  公开了式(I)化合物、包含此类化合物的药物组合物以及使用此类化合物的方法/用途，例如，用于治疗与JAK相关的疾病，如癌症、癌症恶病质或免疫紊乱： 其中 R1 是甲基或乙基 R2 选自甲基、乙基、甲氧基和乙氧基； R3 选自氢、氯、氟、溴和甲基； R4 选自甲基、乙基和- OCH3； R5 和 R6 分别为甲基或氢；以及 R7 选自甲基、乙基、-(CH2)2OH 和-( )2OCH3 或其药学上可接受的盐。
• COMPOUNDS AND METHODS FOR INHIBITING JAK
  申请人：AstraZeneca AB

  公开号：US20170320857A1

  公开（公告）日：2017-11-09

  Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R 1 is methyl or ethyl; R 2 is selected from methyl, ethyl, methoxy and ethoxy; R 3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R 4 is selected from methyl, ethyl and —CH 2 OCH 3 ; R 5 and R 6 are each individually methyl or hydrogen; and R 7 is selected from methyl, ethyl, —(CH 2 ) 2 OH and —(CH 2 ) 2 OCH 3 , or a pharmaceutically acceptable salt thereof.
• US9714236B2
  申请人：——

  公开号：US9714236B2

  公开（公告）日：2017-07-25